(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.04%) $0.927
(0.21%) $10.86
(0.02%) $0.792
(0.03%) $92.60
Live Chart Being Loaded With Signals
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark...
Stats | |
---|---|
Today's Volume | 268 865 |
Average Volume | 473 993 |
Market Cap | 214.47M |
EPS | SEK0 ( 2024-02-28 ) |
Next earnings date | ( SEK0 ) 2024-05-29 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -1.340 |
ATR14 | SEK0.00800 (0.41%) |
Volume Correlation
Saniona AB (publ) Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Saniona AB (publ) Correlation - Currency/Commodity
Saniona AB (publ) Financials
Annual | 2023 |
Revenue: | SEK16.84M |
Gross Profit: | SEK-79.35M (-471.18 %) |
EPS: | SEK-1.290 |
Q4 | 2023 |
Revenue: | SEK5.37M |
Gross Profit: | SEK-18.45M (-343.34 %) |
EPS: | SEK-0.380 |
Q3 | 2023 |
Revenue: | SEK5.45M |
Gross Profit: | SEK3.92M (71.82 %) |
EPS: | SEK-0.380 |
Q2 | 2023 |
Revenue: | SEK3.85M |
Gross Profit: | SEK2.72M (70.57 %) |
EPS: | SEK-0.340 |
Financial Reports:
No articles found.
Saniona AB (publ)
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators